Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Footnotes
  • Version history
  • Article usage
  • Citations to this article
Advertisement

Corrigendum Open Access | 10.1172/jci.insight.165688

PPT1 inhibition enhances the antitumor activity of anti–PD-1 antibody in melanoma

Gaurav Sharma, Rani Ojha, Estela Noguera-Ortega, Vito W. Rebecca, John Attanasio, Shujing Liu, Shengfu Piao, Jennifer J. Lee, Michael C. Nicastri, Sandra L. Harper, Amruta Ronghe, Vaibhav Jain, Jeffrey D. Winkler, David W. Speicher, Jerome Mastio, Phyllis A. Gimotty, Xiaowei Xu, E. John Wherry, Dmitry I. Gabrilovich, and Ravi K. Amaravadi

Find articles by Sharma, G. in: JCI | PubMed | Google Scholar

Find articles by Ojha, R. in: JCI | PubMed | Google Scholar

Find articles by Noguera-Ortega, E. in: JCI | PubMed | Google Scholar

Find articles by Rebecca, V. in: JCI | PubMed | Google Scholar

Find articles by Attanasio, J. in: JCI | PubMed | Google Scholar

Find articles by Liu, S. in: JCI | PubMed | Google Scholar

Find articles by Piao, S. in: JCI | PubMed | Google Scholar

Find articles by Lee, J. in: JCI | PubMed | Google Scholar

Find articles by Nicastri, M. in: JCI | PubMed | Google Scholar

Find articles by Harper, S. in: JCI | PubMed | Google Scholar

Find articles by Ronghe, A. in: JCI | PubMed | Google Scholar

Find articles by Jain, V. in: JCI | PubMed | Google Scholar

Find articles by Winkler, J. in: JCI | PubMed | Google Scholar

Find articles by Speicher, D. in: JCI | PubMed | Google Scholar

Find articles by Mastio, J. in: JCI | PubMed | Google Scholar

Find articles by Gimotty, P. in: JCI | PubMed | Google Scholar

Find articles by Xu, X. in: JCI | PubMed | Google Scholar

Find articles by Wherry, E. in: JCI | PubMed | Google Scholar

Find articles by Gabrilovich, D. in: JCI | PubMed | Google Scholar

Find articles by Amaravadi, R. in: JCI | PubMed | Google Scholar

Published October 24, 2022 - More info

Published in Volume 7, Issue 20 on October 24, 2022
JCI Insight. 2022;7(20):e165688. https://doi.org/10.1172/jci.insight.165688.
© 2022 melanoma et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published October 24, 2022 - Version history
View PDF

Related article:

PPT1 inhibition enhances the antitumor activity of anti–PD-1 antibody in melanoma
Gaurav Sharma, … , Dmitry I. Gabrilovich, Ravi K. Amaravadi
Gaurav Sharma, … , Dmitry I. Gabrilovich, Ravi K. Amaravadi
Inhibiting palmitoyl-protein thioesterase 1 (PPT1), a target of CQ derivatives like hydroxychloroquine (HCQ), enhances the antitumor efficacy of anti-PD-1 Ab in murine melanoma models.
Research Article Oncology Therapeutics

PPT1 inhibition enhances the antitumor activity of anti–PD-1 antibody in melanoma

  • Text
  • PDF
Abstract

New strategies are needed to enhance the efficacy of anti–programmed cell death protein antibody (anti–PD-1 Ab) in cancer. Here, we report that inhibiting palmitoyl-protein thioesterase 1 (PPT1), a target of chloroquine derivatives like hydroxychloroquine (HCQ), enhances the antitumor efficacy of anti–PD-1 Ab in melanoma. The combination resulted in tumor growth impairment and improved survival in mouse models. Genetic suppression of core autophagy genes, but not Ppt1, in cancer cells reduced priming and cytotoxic capacity of primed T cells. Exposure of antigen-primed T cells to macrophage-conditioned medium derived from macrophages treated with PPT1 inhibitors enhanced melanoma-specific killing. Genetic or chemical Ppt1 inhibition resulted in M2 to M1 phenotype switching in macrophages. The combination was associated with a reduction in myeloid-derived suppressor cells in the tumor. Ppt1 inhibition by HCQ, or DC661, induced cyclic GMP-AMP synthase/stimulator of interferon genes/TANK binding kinase 1 pathway activation and the secretion of interferon-β in macrophages, the latter being a key component for augmented T cell–mediated cytotoxicity. Genetic Ppt1 inhibition produced similar findings. These data provide the rationale for this combination in melanoma clinical trials and further investigation in other cancers.

Authors

Gaurav Sharma, Rani Ojha, Estela Noguera-Ortega, Vito W. Rebecca, John Attanasio, Shujing Liu, Shengfu Piao, Jennifer J. Lee, Michael C. Nicastri, Sandra L. Harper, Amruta Ronghe, Vaibhav Jain, Jeffrey D. Winkler, David W. Speicher, Jerome Mastio, Phyllis A. Gimotty, Xiaowei Xu, E. John Wherry, Dmitry I. Gabrilovich, Ravi K. Amaravadi

×

Original citation: JCI Insight. 2020;5(17):e133225. https://doi.org/10.1172/jci.insight.133225

Citation for this corrigendum: JCI Insight. 2022;7(20):e165688. https://doi.org/10.1172/jci.insight.165688

The authors recently became aware that one of the p-TBK1 blot images presented in Figure 6C is the same as that presented in Figure 6D. The authors reviewed the original data and determined that the image in Figure 6C was incorrect. The correct version of Figure 6C is shown below, and the HTML and PDF versions have been updated.

Figure 6

The authors regret the error.

Footnotes

See the related article at PPT1 Inhibition enhances the anti-tumor activity of anti-PD-1 antibody in melanoma.

Version history
  • Version 1 (October 24, 2022): Electronic publication

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Footnotes
  • Version history
Advertisement
Advertisement

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts